Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00755781Phase 3Completed

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

Role: lead

NCT00633373Unknown

Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

Role: lead

NCT00938236Phase 3Terminated

CIS001 Extension Study of Cyclosporine Inhalation Solution

Role: lead

All 3 trials loaded